NCT05082584View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

October 31, 2026

Conditions
Anemia of Chronic Kidney Disease
Interventions
DRUG

Vadadustat

Vadadustat tablet orally once a day for 52 weeks

Trial Locations (1)

07601

Research Site, Hackensack

Sponsors
All Listed Sponsors
lead

Akebia Therapeutics

INDUSTRY

NCT05082584 - Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents | Biotech Hunter | Biotech Hunter